Molecular diagnostics and treatment of patients with the hypereosinophilic syndrome

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 1, 2009, Pages 43-44

  Rothenberg, Marc E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CORTICOSTEROID; HYDROXYUREA; IMATINIB; INTERLEUKIN 5; INTERLEUKIN 5 ANTIBODY; MEPOLIZUMAB; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISOLONE; PREDNISONE; PROTEIN TYROSINE KINASE; RESLIZUMAB; VINCRISTINE;

ARTICLE; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CARDIOTOXICITY; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; EOSINOPHIL COUNT; EOSINOPHILIC ESOPHAGITIS; GASTROINTESTINAL TOXICITY; GENETIC RISK; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPERGLYCEMIA; HYPERTENSION; LIVER TOXICITY; MOLECULAR BIOLOGY; MOOD DISORDER; PATHOPHYSIOLOGY; SKIN ATROPHY; INTERVIEW;

HUMANS; HYPEREOSINOPHILIC SYNDROME; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 63449096316     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Klion AD, Bochner BS, Gleich, GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol. 2006;117:1292-302.
2. Rothenberg ME, Klion AD, Raufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358: 1215-1228.